Phathom Pharmaceuticals (PHAT) Current Assets (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Current Assets data on file, last reported at $276.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $276.6 million, up 4.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.6 million (up 4.41% YoY), and the FY2025 annual result was $229.0 million, down 36.42% from the prior year.
• Current Assets grew to $276.6 million in Q1 2026 per PHAT's latest filing, from $229.0 million in the prior quarter.
• Over five years, Current Assets peaked at $397.4 million in Q4 2023 and troughed at $139.8 million in Q1 2023.
• A 5-year average of $253.6 million and a median of $229.0 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets soared 147.6% in 2023, then slumped 44.42% in 2025.
• A 5-year view of Current Assets shows it stood at $160.5 million in 2022, then jumped by 147.6% to $397.4 million in 2023, then dropped by 9.38% to $360.1 million in 2024, then tumbled by 36.42% to $229.0 million in 2025, then grew by 20.79% to $276.6 million in 2026.
• Business Quant data shows PHAT's Current Assets at $276.6 million in Q1 2026, $229.0 million in Q4 2025, and $207.8 million in Q3 2025.